Pharmacological inhibition of restenosis: learning from experience.
Shaw
L A
LA
Department of Vascular Diseases and Osteoporosis, Sandoz Pharma, Basel, Switzerland.
Rudin
M
M
Cook
N S
NS
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001024:Aortic Valve Stenosis / Q000517:prevention & control*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000601:surgery; D006801:Humans; D011817:Rabbits; D051381:Rats; D012307:Risk Factors; D014661:Vasoconstriction
D000806:Angiotensin-Converting Enzyme Inhibitors